Nontuberculous Mycobacterium Treatment Market Size & Share, by Drug Type (Clarithromycin, Azithromycin, Rifampin, Rifabutin, Ethambutol, Streptomycin, Amikacin); End-user (Hospitals, Private Clinics, Drug Stores, Retail Pharmacy) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 4072
  • Published Date: Aug 16, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Nontuberculous Mycobacterium Treatment Market size was valued at USD 9.11 billion in 2023 and is likely to reach USD 12.72 billion by 2036, registering around 2.6% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of nontuberculous mycobacterium treatment is estimated at USD 9.3 billion. The growth of the market can be attributed to the increasing prevalence of nontuberculous mycobacterial lung disease, especially amongst the elderly population across the globe. Moreover, the rising geriatric population on a global level, is further estimated to boost the market growth. According to the data by the World Bank, 723,484,054 individuals were aged above 64 years of age, as of 2020. Furthermore, the high occurrence of various lung-related issues amongst people are further projected to boost the market growth. As per the data by the National Organization for Rare Disorder, chronic lung infection is the most common complication affecting approximately 94% of individuals. Additionally, increasing health awareness amongst people, government initiatives to provide efficient health facilities, and growing health expenditure are estimated to boost the market growth.


Nontuberculous Mycobacterium Treatment Market
Get more information on this report: Request Free Sample PDF

Nontuberculous Mycobacterium Treatment Sector: Growth Drivers and Challenges

Growth Drivers

  • Increasing Prevalence of Nontuberculous Mycobacterium Infection
  • Rising Geriatric Population Globally

Challenges

  • High Cost of Treatment
  • Unavailability of Advanced Treatment Methods in Developing Regions

Nontuberculous Mycobacterium Treatment Market: Key Insights

Base Year

2023

Forecast Year

2024–2036

CAGR

2.6%

Base Year Market Size (2023)

USD 9.11 billion

Forecast Year Market Size (2036)

USD 12.72 billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Nontuberculous Mycobacterium Treatment Segmentation

The market is segmented by end-user into hospitals, private clinics, drug stores, retail pharmacy, and others, out of which, the hospitals segment is anticipated to hold a substantial share in the global market over the forecast period on account of growing patient footfall in hospitals. Additionally, hospitals tend to a vast variety of patients leading to higher popularity of hospitals amongst people, which is estimated to boost the segment.

Our in-depth analysis of the global market includes the following segments:

           By Drug Type

  • Clarithromycin
  • Azithromycin
  • Rifampin
  • Rifabutin
  • Ethambutol
  • Streptomycin
  • Amikacin
  • Others

             By End-User

  • Hospitals
  • Private Clinics
  • Drug Stores
  • Retail Pharmacy
  • Others

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Nontuberculous Mycobacterium Treatment Industry - Regional Synopsis

On the basis of geographical analysis, the global nontuberculous mycobacterium treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Asia Pacific industry is predicted to hold largest revenue share by 2036, on the back of improving healthcare infrastructure, along with growing geriatric population in the region.

The market in the North America region is anticipated to gain the largest market share throughout the forecast period on the back of high prevalence of nontuberculous mycobacterium infections. The high healthcare expenditure, presence of major pharmaceutical companies, and increasing research activities for the development of new drugs, are further estimated to boost the market growth. According to the statistics by the World Bank, in 2018, North America spent USD 10,050.516 for the healthcare of every individual. The total healthcare expenditure accounted for 16.415% of the total GDP of North America in the same year.  
 

Research Nester
Nontuberculous-Mycobacterium-Treatment -Market-Share
Get more information on this report: Request Free Sample PDF

Companies Dominating the Nontuberculous Mycobacterium Treatment Landscape

    • Tercica, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis 
    • Atara Biotherapeutics, Inc.
    • Kadmon Holdings, Inc.
    • Beyond Air Inc.
    • Savara Inc.
    • RedHill Biopharma Ltd.
    • Insmed Inc.
    • Novartis AG
    • GlaxoSmithKline plc
    • TFF Pharmaceuticals, Inc.

In the News

  • January 6, 2022: RedHill Biopharma Ltd., the specialty biopharmaceutical company, entered into an agreement with Gaelan Medical Trade LLC for the sale of drug Talicia (omeprazole magnesium, amoxicillin and rifabutin) in the United Arab Emirates (UAE).

  • February 20, 2021: Koninklijke Philips N.V. announced the acquisition of BioTelemetry, Inc., a leading provider of remote diagnostics and monitoring.

Author Credits:  Radhika Pawar


  • Report ID: 4072
  • Published Date: Aug 16, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of nontuberculous mycobacterium treatment is estimated at USD 9.3 billion.

Nontuberculous Mycobacterium Treatment Market size was valued at USD 9.11 billion in 2023 and is likely to reach USD 12.72 billion by 2036, registering around 2.6% CAGR during the forecast period i.e., between 2024-2036. The growing prevalence of nontuberculous mycobacterium infections will boost the market growth.

Asia Pacific industry is predicted to hold largest revenue share by 2036, on the back of improving healthcare infrastructure, along with growing geriatric population in the region.

The major players in the market are Atara Biotherapeutics, Inc., Kadmon Holdings, Inc., Beyond Air Inc., Savara Inc., RedHill Biopharma Ltd., Insmed Inc., Novartis AG, GlaxoSmithKline plc, and TFF Pharmaceuticals, Inc.
Nontuberculous Mycobacterium Treatment Market Report Scope
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample